Form 4: BioCryst Pharmaceuticals CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
BioCryst Pharmaceuticals CEO, Jon P. Stonehouse, disposed of 27,525 shares to cover tax obligations related to vesting restricted stock units.
Summary
- Jon P. Stonehouse, the President and CEO of BioCryst Pharmaceuticals, disposed of 27,525 common stock shares on December 14, 2024.
- The shares were sold at a price of $7.53 per share.
- This transaction was to cover tax withholding obligations related to the vesting of previously granted restricted stock units and does not represent a sale by the reporting person.
- Following the transaction, Mr. Stonehouse directly owns 1,101,019 shares of BioCryst common stock.
- Mr. Stonehouse also indirectly owns 20,000 shares through his wife as co-trustee of the Caroline Stonehouse Irrevocable Trust and another 20,000 shares through his wife as co-trustee of the Samuel Stonehouse Irrevocable Trust.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's performance.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are a common practice across the pharmaceutical industry.
- Many companies use restricted stock units as part of executive compensation packages, leading to similar tax-related sales.
- The sale by Mr. Stonehouse is consistent with standard practices for executives managing their equity holdings.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale for tax purposes.
- The sale does not indicate any change in the CEO's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 12/14/2024 | Date of the stock transaction. |
| 12/17/2024 | Date the form was signed. |
Keywords
BioCryst Pharmaceuticals, BCRX, Jon P. Stonehouse, insider trading, stock sale, tax obligations, restricted stock units, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.